Advertisement
A vs LAB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Buy and LAB is a Hold.
Momentum Indicator for A turns positive, indicating new upward trend
A saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 61 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +4.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where A advanced for three days, in 188 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 141 of 209 cases where A Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for A moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 21 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for A turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 28 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where A declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
A broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 5 (best 1 - 100 worst), indicating outstanding price growth. A’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.806) is normal, around the industry mean (66.046). P/E Ratio (34.921) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (1.447) is also within normal values, averaging (3.473). Dividend Yield (0.006) settles around the average of (0.002) among similar stocks. P/S Ratio (5.910) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. A’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
LAB sees MACD Histogram crosses below signal line
LAB saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 07, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 55 instances where the indicator turned negative. In 49 of the 55 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LAB as a result. In 79 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
LAB moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LAB crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where LAB advanced for three days, in 196 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
LAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 110 of 123 cases where LAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 50 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.462) is normal, around the industry mean (2.874). P/E Ratio (2.889) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (3.300) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. LAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
A | LAB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 61 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 59 Fair valued | |
PROFIT vs RISK RATING 1..100 | 91 | 100 | |
SMR RATING 1..100 | 45 | 50 | |
PRICE GROWTH RATING 1..100 | 5 | 80 | |
P/E GROWTH RATING 1..100 | 36 | 71 | |
SEASONALITY SCORE 1..100 | 85 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (24) in the Biotechnology industry is somewhat better than the same rating for LAB (59) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than LAB’s over the last 12 months.
A's Profit vs Risk Rating (91) in the Biotechnology industry is in the same range as LAB (100) in the Medical Specialties industry. This means that A’s stock grew similarly to LAB’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is in the same range as LAB (50) in the Medical Specialties industry. This means that A’s stock grew similarly to LAB’s over the last 12 months.
A's Price Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for LAB (80) in the Medical Specialties industry. This means that A’s stock grew significantly faster than LAB’s over the last 12 months.
A's P/E Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for LAB (71) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than LAB’s over the last 12 months.
| A | LAB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 75% | N/A |
| Stochastic ODDS (%) | 1 day ago 71% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 70% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 62% | 1 day ago 89% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 63% | 1 day ago 84% |
| Advances ODDS (%) | 2 days ago 62% | 18 days ago 82% |
| Declines ODDS (%) | 4 days ago 63% | 15 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 71% | 1 day ago 85% |
| Aroon ODDS (%) | 1 day ago 67% | 1 day ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green while LAB’s FA Score has 0 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- LAB’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 3 TA indicator(s) are bullish while LAB’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 3 bullish, 5 bearish.
- LAB’s TA Score: 4 bullish, 5 bearish.
Price Growth
A (@Medical Specialties) experienced а -0.95% price change this week, while LAB (@Medical/Nursing Services) price change was -3.46% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.29%. For the same industry, the average monthly price growth was -6.63%, and the average quarterly price growth was +42.53%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.
Reported Earning Dates
A is expected to report earnings on Nov 23, 2026.
LAB is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Medical Specialties (-3.29% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-1.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| METD | 14.22 | 0.96 | +7.24% |
| Direxion Daily META Bear 1X ETF (METD) | |||
| MAMB | 23.46 | 0.15 | +0.64% |
| Monarch Ambassador Income Index ETF (MAMB) | |||
| PRF | 56.40 | 0.08 | +0.14% |
| Invesco RAFI US 1000 ETF (PRF) | |||
| IXG | 129.83 | -0.01 | -0.01% |
| iShares Global Financials ETF (IXG) | |||
| KJUN | 28.87 | -0.02 | -0.06% |
| Innovator U.S. Small Cap Power Buffer ETF - June (KJUN) | |||